Featured Research

from universities, journals, and other organizations

Common genetic pathway could be conduit to pediatric tumor treatment

Date:
November 7, 2013
Source:
Johns Hopkins Medicine
Summary:
Investigators have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

In laboratory studies, researchers found that the pathway, called mammalian target of rapamycin (mTOR), was highly active in pediatric low-grade gliomas, and that mTOR activity could be blocked using an experimental drug, leading to decreased growth of these tumors.

"We think mTOR could function as an Achilles heel," says study co-author Eric Raabe, M.D., Ph.D., an assistant professor of pediatrics, oncology and pathology at the Johns Hopkins Kimmel Cancer Center. "It drives cancer growth, but when mTOR is inhibited, the tumor falls apart." The work was described Nov. 7 in the journal Neuro-Oncology.

Overall, brain tumors affect more than 4,000 children each year in the United States, and they are the leading cause of cancer deaths in children, according to Raabe. Low-grade gliomas are the most common group of tumors of the central nervous system in children. Current treatments for these tumors include surgery and chemotherapy, which often cause significant side effects. Many of these tumors are located in areas like the optic pathway, where they can't be easily removed by surgery without causing damage, including blindness. In addition to vision loss, some of Raabe's patients have endured paralysis or learning problems as a result of the tumor or treatment.

"Even though these tumors are considered 'low grade' and not particularly aggressive, many patients suffer severe, life-altering symptoms, so we desperately need better therapies," says Raabe.

For the study, the Johns Hopkins investigators studied tissue samples from 177 pediatric low-grade gliomas, including the most common type -- tumors called pilocytic astrocytomas -- from patients treated at Johns Hopkins and other centers. They also tested the effect of blocking mTOR with an investigational agent known as MK8669 (ridaforolimus) in two pediatric low-grade glioma cell lines.

The mTOR pathway has been shown to be active in a variety of cancers, and drugs that block proteins in the pathway, such as rapamycin, are widely available. The pathway signals through two protein complexes, mTORC1 and mTORC2, which lead to increased cell growth and survival.

The researchers found activity of the mTORC1 pathway in 90 percent of low-grade gliomas studied, and 81 percent of tumors showed activity of both mTORC1 and mTORC2. Components of the mTOR pathway were more commonly found in tumors from optic pathways compared with those from other areas of the brain, according to Fausto Rodriguez , M.D., senior study author and assistant professor of pathology and oncology at Johns Hopkins.

The scientists also found that the mTOR-blocking drug caused up to a 73 percent reduction in cell growth over six days in one cell line, and up to a 21 percent decrease in cell growth over four days in a second cell line.

"Since the pathways are more active in some areas of the brain, compared with others, it suggests that the outcomes of drug treatments targeting those pathways may differ as well," says Rodriguez.

Rodriguez and Raabe say they hope to build on the research in animal models and test additional inhibitors.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Marianne Hütt-Cabezas, Matthias A. Karajannis, David Zagzag, Smit Shah, Iren Horkayne-Szakaly, Elisabeth J. Rushing, J. Douglas Cameron, Deepali Jain, Charles G. Eberhart, Eric H. Raabe, and Fausto J. Rodriguez. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro-Oncology, November 2013

Cite This Page:

Johns Hopkins Medicine. "Common genetic pathway could be conduit to pediatric tumor treatment." ScienceDaily. ScienceDaily, 7 November 2013. <www.sciencedaily.com/releases/2013/11/131107093828.htm>.
Johns Hopkins Medicine. (2013, November 7). Common genetic pathway could be conduit to pediatric tumor treatment. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/11/131107093828.htm
Johns Hopkins Medicine. "Common genetic pathway could be conduit to pediatric tumor treatment." ScienceDaily. www.sciencedaily.com/releases/2013/11/131107093828.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) — The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins